Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisGordon R. Bernard, Charles J. Fisher, Jean‐Louis Vincent et al.|New England Journal of Medicine|2001Cited by 6.1k
The Immunopathogenesis of Sepsis in Elderly PatientsSteven M. Opal, E. Wesley Ely, Timothy D. Girard|Clinical Infectious Diseases|2005Cited by 486
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsisE. Wesley Ely, Gordon R. Bernard, Pierre‐François Laterre et al.|Critical Care Medicine|2003Cited by 283
SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)Amy D. Proal, E. John Wherry, Michela Locci et al.|Nature Immunology|2023Cited by 281